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ABSTRACT 
Objective: The present investigation aims to formulate and evaluate proniosomes of clopidogrel bisulphate for improving its dissolution 
characteristics. 
Methods: The slurry method was used for the preparation of proniosomes of clopidogrel using cholesterol, sorbitan monostearate (Span 
60) and maltodextrin as a carrier. Clopidogrel proniosomes were evaluated for their entrapment efficiency and in vitro drug release. The 
best formula (F1) that achieved maximum drug release was further evaluated by measurement of the angle of repose, morphological 
examination, determination of vesicle size, determination of zeta potential, Fourier transform infrared spectroscopy and differential 
thermal analysis. The in vivo behavior of the selected proniosomal formula (F1) was studied by measuring the antiplatelet activity in adult 
male mice. 
Results: The entrapment efficiency of clopidogrel proniosomes was in the range of 83.04±1.99 to 90.14±0.30. % drug released from proniosomal 
formulations was in the range of 79.73±0.35 to 97.70±1.10 % within 4 h. Clopidogrel proniosomes significantly enhanced the in vitro release of 
clopidogrel compared with the plain drug that achieved 61.77±2.22 % drug release. F1 significantly (p ≤ 0.001) increased the bleeding time and 
bleeding volume and significantly (p ≤ 0.05)  prolonged prothrombin time and decreased prothrombin activity and increased the international 
normalized ratio (INR) compared to plain clopidogrel.  
Conclusion: The present investigation introduced proniosomes as a promising carrier for clopidogrel that could enhance its dissolution and 
pharmacological effect. 
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Clopidogrel bisulfate is a weak base that is known chemically as Methyl 
(S)-α-(2chlorophenyl)-6,7di-hydrothieno[3,2-c]pyridine-5(4H)-acetate 
sulfate. Clopidogrel is a potent antiplatelet agent that is widely used 
for the prevention of coronary artery diseases and treatment of 
vascular thrombosis. However, it is of low aqueous solubility and 
therefore, it has low oral bioavailability (less than 50%). 
Enhancement of solubility is of critical concern in improving 
dissolution rate and bioavailability. Recently, different 
nanotechnology techniques have been used to increase the 
dissolution rate and bioavailability of many drugs [1, 2]. 
Liposomes are phospholipid nano-vesicles that are used as drug 
carriers, but they suffer from several disadvantages like physical and 
chemical instability [3, 4]. Therefore, special storage conditions and 
handling are required [5]. Niosomes are non-ionic surfactant 
vesicles that protect the drug against enzymatic degradation and 
improve drug permeability by their surface-active properties [6]. 
Niosomes are more stable chemically than liposomes, but they are 
also physically unstable due to the possibility of aggregation, fusion, 
and leakage of vesicles. Proniosomes are free-flowing powder form 
of niosomes [7]. Proniosomes could overcome physical instability 
problems of niosomes [8] and offer better convenience of storage 
and transportation. Following hydration, proniosomes are 
converted to niosomes [9, 10]. 
Though the oral drug delivery is the most common and preferred 
route of drug administration, failure of the conventional delivery 
of many drugs may happen due to poor drug absorption and 
highly fluctuated drug plasma levels. Lipid nano-vesicles like 
proniosomes have various advantages over conventional drug 
delivery systems because they act as drug reservoirs that 
enhance both drug solubilization and permeation. Moreover, 
proniosomes provide controlled drug release to deliver the 
effective dose of the drug to its target site [8, 9]. 
The aim of this study is to formulate proniosomes of clopidogrel by 
the slurry method for enhancement of dissolution and 
pharmacological effect of clopidogrel. 
MATERIALS AND METHODS 
Materials 
Clopidogrel was a gift sample from the Egyptian International 
Pharmaceutical Industries Co., EPICO, Egypt. Cholesterol and 
maltodextrin were obtained from Sigma Chemical Co. (St. Louis, MO, 
USA). Potassium dihydrogen phosphate and sodium hydroxide were 
purchased from PureLab, USA. Sorbitan monostearate (Span 60) was 
purchased from Alpha Chemica, Mumbai, India. Ethanol and 
chloroform were obtained from El-Nasr Pharmaceutical Chemical 
Company, Cairo, Egypt. 
Methods 
Preparation of clopidogrel proniosomes 
Clopidogrel proniosomes were formulated by the slurry method 
using maltodextrin as a carrier, table 1. Accurately weighed 
amounts of clopidogrel, Span 60 and cholesterol were dissolved 
in chloroform/ethanol mixture (2:1 v/v). The resultant solution 
is added to a round-bottom flask containing maltodextrin carrier 
to form the slurry. The organic solvents were removed using a 
rotary evaporator (Buchi rotavapor R-3000, Switzerland) that 
was adjusted to 70 rpm, at 45±2 °C under reduced pressure until 
the mass in the round-bottom flask become dry free-flowing 
product [13]. The formulated proniosomes were stored in well-
closed containers to be used for further studies. 
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Table 1: Composition of clopidogrel loaded proniosomes 
Formulation Code Ratio(µmol) (Cholesterol: span60) Maltodextrin (mg) 
F1 40: 210 210 
F2 60: 190 190 
F3 80: 170 170 
F4 100: 150 150 
F5 120: 130 130 
F6 140: 110 110 
F7 160: 90 90 
* clopidogrelEach formulation containing  bisulphate 98 mg (which is equivalent to 75 mg of clopidogrel base), *
 
Preparation of niosomes from clopidogrel proniosomes 
The niosomal clopidogrel dispersion was directly prepared by hydrating 
the proniosomal powder with distilled water at 80 °C±2 °C using a 
vortex mixer (BOECO, Germany) for 3 min [14]. The resulting niosomal 
dispersion was used for estimation of the entrapment efficiency. The 
niosomal dispersion was sonicated twice for 30 sec using sonicator 
(Hielscher Ultrasonics, Germany) and stored at 4 °C for further studies. 
Determination of entrapment efficiency of clopidogrel 
proniosomes 
Entrapment efficiency of clopidogrel in proniosome-derived 
niosomes was done by centrifugation method. The niosomal 
dispersion prepared before by hydration of clopidogrel proniosomal 
powder was centrifuged at 6000 rpm for 1h at 4 °C [15] using a 
cooling ultracentrifuge (Biofuge, primo Heraeus, Germany). The 
whole supernatant was analyzed for the drug content by using UV 
spectrophotometer (Shimadzu U-V 1700, Japan). Encapsulation 
efficiency was calculated as follows:  
1 g of Carrier (maltodextrin) per 1 mmol of 
Span 60  
EE(%)  =  (A1 − A2) x 100/A1 
Where A1 =  Initial amount of drug, A2 = Amount of drug in the 
supernatant 
In vitro release of clopidogrel proniosomes 
In vitro release of clopidogrel proniosomes and aqueous drug dispersion 
was performed using modified Franz di ffusion cells. Cellulose membrane 
was mounted between donor and receptor compartments. The receptor 
medium was phosphate buffer solution (PBS) pH 6.8 (containing 1% 
sodium lauryl sulphate) that maintained at 37 °C±0.5 °C and stirred at 50 
rpm. The proniosomal formulations and aqueous drug dispersion were 
loaded on the donor compartment. Samples were withdrawn at di fferent 
time intervals and replaced by the same amount of fresh bu ffer. The drug 
concentrations were determined using UV spectrophotometer. Triplicate 
experiments were performed. The results were expressed as mean 
values±SD [2, 16]. 
The similarity factor test was used to compare the overall 
dissolution profiles and to determine the similarity in the pattern of 
drug release of plain drug and different proniosomal formulations 
[17]. The two preparations are said to be similar if the value of fR2R lies 
between 50 and 100. fR2R is calculated by the formula given below:  
𝑓𝑓2 = 50. 𝑙𝑙𝑙𝑙𝑙𝑙 ��1 +
1
𝑛𝑛






Where, RRtR and TRtR are percentages of drug dissolved at a specified 
time from the standard and test formulations respectively, n = no of 
sampling points. 
Kinetic treatment 
The release kinetics and mechanism of the in vitro release of 
clopidogrel proniosomes were studied by treating the data of drug 
release using different mathematical models as zero-order, first-
order kinetics and Higuchi model [18]. 
Zero-order model: A = Kot  
First-order model: ln (1 −  A) =  − K1t  
Higuchi model: A = KHt1/2  
Where: A is the fraction of drug released in time t, KRoR is the rate 
constant of zero-order, KR1R is the rate constant of first-order and KRHR 
is the rate constant of Higuchi diffusion model. 
Evaluation of the selected formula of clopidogrel proniosomes 
Clopidogrel proniosomal formulation that achieved the best in vitro 
release was evaluated by measurement of the angle of repose, 
Fourier-transform infrared spectroscopy (FTIR), differential thermal 
analysis (DTA), morphological examination and determination of 
vesicle size and zeta potential.  
Micromeritic properties 
The flow properties of the chosen proniosomal powder were 
determined by measurement of the angle of repose. The angle of repose 
of both maltodextrin and the chosen proniosomal powder was 
determined by the funnel method. A funnel was fixed at a certain height 
so that the outlet orifice of the funnel is 5 cm above a graph paper placed 
on a horizontal surface. Maltodextrin or proniosome powder was flowed 
down through the funnel until the apex of the powder pile just touched 
the funnel tip [19]. The angle of repose was estimated as follows:  
Tan θ = h/r 
(θ is the angle of repose, h is the height of the powder pile and r is 
the radius of powder pile). 
Photomicroscopic examination 
The formation of the noisomal vesicles upon hydration of the 
proniosomal powder was investigated by photomicroscopic 
examination. The selected proniosomal powder was spread on a 
glass slide and few microliters of distilled water (80 °C±2 °C) were 
added dropwise. The morphology of the selected proniosomal 
powder (F1) and formation of the niosomal vesicles were observed 
under a light microscope (Coslabs micro, India) [8, 17].  
Scanning electron microscopy (SEM)  
The morphology of the chosen proniosomal formula derived 
niosomes was examined by the scanning electron microscope (SEM) 
(Jeol, JSM-6360, Japan). The optimized dispersion was firstly diluted 
with distilled water and dropped on the copper mesh. Few minutes 
after drying of excessive circumjacent liquid, 1% phosphotungstic 
acid was added for a few minutes as a negative stain. The 
overflowed solution was sipped up and dried in the air [18, 19]. 
Vesicle size and zeta potential determination 
Determination of vesicle size and zeta potential was performed for 
investigating the colloidal characters of the chosen proniosomal formula 
(F1). The selected proniosomal formula was hydrated with distilled 
water (80 °C±2 °C) for the formation of the niosomal vesicles. The 
niosomal dispersion was suitably diluted by distilled water. Then, laser 
scattering particle size analyzer (MALVERN ZETASIZER, MAL500999) 
was used for estimation of vesicle size and zeta potential [23]. 
Fourier transform infrared spectroscopy (FT-IR)  
Fourier transform infrared spectroscopy was performed using FTIR 
spectrometer (FT-IR Shimadzu 8300 Japan). Samples of clopidogrel, 
Span 60, cholesterol, maltodextrin, plain proniosomes and the 
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chosen clopidogrel proniosomal formula were used. All these 
samples were grounded and mixed with potassium bromide to form 
KBr pellets in a hydraulic press (Kimaya Engineers, Maharastra, 
India). The scanning range was 4000–400 cm−1
3 h after oral administration of clopidogrel and the selected clopidogrel 
proniosomal formula (F1), all mice were anesthetized with diethyl ether. 
Blood samples were collected via cardiac puncture and collected into 
tubes containing sodium citrate. The citrated plasma was used to 
evaluate the prothrombin time and activity. 
 using PerkinElmer 
instrument (Spectrum RXI-5.31, UK) [1, 21]. 
Differential thermal analysis (DTA) study  
DTA was used to investigate the change in the crystalline state of 
clopidogrel in the chosen proniosomal formula using differential thermal 
analyzer (Shimadzu DTA–50 module, Kyoto, Japan). The rate of heating 
was 10 °C/min. The samples of clopidogrel, Span 60, cholesterol, 
maltodextrin, plain proniosomes, and the chosen clopidogrel 
proniosomal formula were heated in the range of 30-400 °C under dry 
nitrogen flow rate of 15 ml/min [22, 23]. 
In vivo study  
Animals 
White male albino mice weighing 20-30 gm were used in this 
experiment. Mice were purchased from the National Research 
Center (Dokki, Giza, Egypt) and housed in a pathogen-free facility in 
sawdust bedded cages. The animal rooms were maintained at [25±2] 
°C with 50% relative humidity and a 12 h light: dark cycle. All the 
tested mice were acclimatized under standard conditions in the 
animal house for at least two weeks prior to the experiments. The 
study protocol and animal use were approved by The Ethical 
Committee of Faculty of Pharmacy, Kaferelsheikh University. All the 
experimental procedures were performed in accordance with the 
recommendations of the ARRIVE guidelines [27] and comply with 
European Union Directive as 2010/63/EU [28] and the U. K. Animals 
(Scientific Procedures) Act, 1986 (ASPA) [29].  
Experimental protocol 
Mice were divided into 3 groups (10 mice each) the first group was 
treated with an aqueous dispersion of clopidogrel bisulfate (20 
mg/kg) as a single oral dose (Standard group). The second group 
was gavaged with a single dose of clopidogrel proniosomal formula 
(F1) equivalent to 20 mg/kg orally (Test group). The third group 
was served as the control group. Mice in this group received only 
distilled water. Five mice of each group were used to evaluate 
platelet aggregation through measuring bleeding time and bleeding 
volume. The other five mice were integrated into the evaluation of 
coagulation activity markers [30]. 
Platelet aggregation inhibition assay  
This study was done for studying the platelet aggregation inhibition 
effect of clopidogrel bisulfate and the selected clopidogrel 
proniosomal formula (F1). Five mice of each group were 
anesthetized using diethyl ether after 1h of treatment. The tails of 
the anesthetized mice were cut (about 0.5 cm from the distal end of 
the tail) then embedded in tubes containing 2 ml of phosphate saline 
buffer (PH 7.4 at 37 ° C). The time until the bleeding stopped was 
detected using a stopwatch. The collected blood volume was then 
measured. The bleeding time and the bleeding volume were 
recorded 1h and 3 h after oral administration of the plain drug and 
the selected clopidogrel proniosomal formula (F1) [31]. 
Detection of coagulation profile 
Assay of prothrombin time and activity were done according to kits' 
instructions (EGY-CHEM for lab technology, Badr City, Egypt). 
Briefly, normal citrated plasma was added to tissue thromboplastin. 
The extrinsic clotting mechanism is then initiated forming a solid gel 
clot within a specified period of time. The test was made in triplicate 
and the results are the mean of three measurements. The 
international normalized ratio (INR) was calculated as the ratio 
between the mean of the prothrombin time of mouse plasma in 
seconds and mean of normal prothrombin time (MNPT) [29, 30]. 
Statistical analysis 
Statistical analysis was performed using one-way analysis of 
variance (ANOVA) using Graph Pad Prism version 7 software. The 
differences were considered to be significant if P<0.05. 
RESULTS AND DISCUSSION 
Preparation of clopidogrel proniosomes 
Clopidogrel Proniosomes were prepared by the slurry method. Span 60 
was chosen as the non-ionic surfactant that facilitates the formation of 
stable vesicles as it has a high phase transition temperature. Moreover, 
Span 60 could enhance the oral delivery of clopidogrel from the 
proniosomal vesicles [34]. Cholesterol was used to improve the 
encapsulation efficiency and stability of the prepared vesicles. 
Maltodextrin was chosen as the coating carrier [15]. Solvents used were 
chloroform and ethanol (2:1) because clopidogrel and lipids are soluble 
in this mixture and also ethanol is less toxic than methanol [11]. The 
ratio of cholesterol to Span 60 was changed from 40: 210 to160: 90 
while keeping the total lipid constant at 250 µM [13].  
Preparation of niosomes from clopidogrel proniosomes 
Clopidogrel niosomes were easily and directly formed after 
hydration of proniosome powder with distilled water at 80±2 °C. 
Vesicular structures were formed over the surface of maltodextrin 
that may be attributed to swelling of the lipid bilayer that 
transformed into multilamellar vesicular structures with gentle 
agitation [15]. The multi-lamellar vesicles are further converted to 
unilamellar niosomal vesicles by sonication. 
Determination of entrapment efficiency of clopidogrel 
proniosomes  
The entrapment efficiency of clopidogrel proniosomes was in the range 
of 83.04±1.99 to 90.14±0.30, table 2. High values of encapsulation 
efficiency may be attributed to the poor water solubility of clopidogrel 
and its dissolving in the lipid bilayers of niosomal vesicles [32, 33].  
F4 showed the highest encapsulation efficiency of 90.14±0.30%. As the 
ratio of cholesterol to Span 60 increased, the entrapment efficiency 
increased. That may be explained by the ability of cholesterol to increase 
the bilayer rigidity by intercalation between the bilayers of non-ionic 
surfactants [37]. However, very high cholesterol concentration was 
found to be of a lowering effect on the entrapment efficiency of the drug. 
This could be due to the fact that cholesterol beyond a certain level has 
the ability to disrupt the regular bilayered structure leading to 
decreasing drug entrapment [13]. Moreover, that may be attributed to 
competition between clopidogrel and cholesterol for packing in the 
limited sites in the bilayered structure of proniosomal vesicles thus 
excluding clopidogrel and disrupting the well-ordered bilayered 
structure [35, 36]. 
 
Table 2: Entrapment efficiency of clopidogrel proniosomes 








*Data are expressed as mean±SD, n=3 
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The ANOVA analysis of entrapment efficiency of proniosomal 
formulations showed that there was significant difference in entrapment 
efficiency between different clopidogrel proniosomal formulations as the 
ratio of cholesterol to Span 60 changed from 40: 210 to160: 90, table 3. F 
values were above the critical F values and that made P values<0.05 
(threshold level). Thus, the null hypothesis (H0
 
) is rejected. 
 
Table 3: ANOVA analysis of entrapment efficiency of clopidogrel proniosomes 
SS DF MS F P value 
Difference (between groups) 140.4 6 23.41 8.86 0.0004 
Difference (within groups) 36.99 14 2.642   
Total 177.4 20    
 
In vitro release of clopidogrel proniosomes 
From fig. 1, the in vitro release of clopidogrel proniosomal 
formulations was in the range of 79.73±0.35 to 97.70±1.10 within 4 
h. It is observed that the results of entrapment efficiency are 
consistent with those of % drug released, as F1 composed of 
cholesterol and Span 60 (40:210) molar ratio with the lowest 
entrapment efficiency showed the highest % drug released. That 
was in good agreement with results reported by Singh et al.(2011) 
who concluded that niosomes that had the highest entrapment 
efficiency exhibited the lowest in vitro drug release due to 
decreasing drug efflux [36]. 
 
 
Fig. 1: In vitro release of plain clopidogrel and its proniosomal formulations, *
 
It is concluded that as the molar ratio of cholesterol to surfactant 
increased, %drug released decreased. That may be explained by a 
marked reduction in the efflux of the drug due to membrane 
stabilizing ability of cholesterol and its ability to abolish the gel-to-
liquid phase transition of niosomal systems [13].  
Data are expressed as mean±SD, n=3 
However, a further increase in the amount of cholesterol beyond certain 
value caused disruption of the bilayered structure of the vesicles leading 
to higher drug release [20]. ANOVA analysis showed that increasing the 
molar ratio of cholesterol to Span60 from 40: 210 to 160: 90 resulted in 
significant (p<0.001) effect on % drug released, table 4. 
 
Table 4: ANOVA analysis of in vitro release of clopidogrel proniosomes 
 SS DF MS F  P value 
Difference (between groups) 624.5 6 104.1 25.36 P<0.0001 
Difference (within groups) 57.47 14 4.105   
Total 682 20    
 
These results were in agreement with results reported by Shilakari 
et al.(2016) [40] who found that higher levels of cholesterol might 
compete with the drug for the packing space within the bilayer 
decreasing the stability of the bilayered vesicles.  
An aqueous dispersion of plain drug achieved 61.77±2.22 % drug 
release after 4 h. Higher dissolution profile obtained with the 
proniosomal formulations than the plain drug might be due to an 
enhancement of solubility of clopidogrel by the non-ionic surfactant 
or due to change in clopidogrel structure from crystalline to 
amorphous state in proniosomal vesicles [31]. Moreover, it could be 
attributed to adsorption of lipid coat of proniosomal vesicles on 
maltodextrin increasing the effective surface area [13]. ANOVA 
analysis showed that incorporation of clopidogrel into proniosomes 
resulted in a significant increase in % drug released compared to the 
plain drug (p<0.001), table 5. 
 
Table 5: ANOVA analysis of in vitro release of clopidogrel proniosomes in comparison to plain drug 
 SS DF MS F  P value 
Difference (between groups) 2431 7 347.3 82.54 P<0.0001 
Difference (within groups) 67.32 16 4.208   
Total 2498 23    
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The dissolution profile of different proniosomal formulations 
was compared with plain drug using the similarity factor test, 
table 6. The estimated values of f2
Formulation code 
 were found to be less than 50. 
Therefore, it is obvious that there is a significant difference in 
drug release between different proniosomes in comparison to 
clopidogrel. 
  









Based on the previous results, formula F1 that achieved the highest % drug release after 4h (97.70±1.10%) and had 83.04±1.99% encapsulation 
efficiency of the drug was chosen for further investigation. 
 
Kinetic treatment 
To find out the mechanism and order of drug release, data of in vitro 
release of clopidogrel formulations were fitted into different kinetic 
models, table 7. The correlation coefficient values indicated that the 
profile of drug release followed Higuchi diffusion model. These 
results indicated that the transport mechanism of the drug from 
clopidogrel proniosomes is by diffusion [41]. 
 
Table 7: Kinetic parameters of clopidogrel proniosomes 
Formula Zero-order First order Higuchi model 
F1 0.987 0.970 0.998 
F2 0.991 0.990 0.998 
F3 0.991 0.990 0.999 
F4 0.992 0.995 0.999 
F5 0.995 0.990 0.999 
F6 0.993 0.983 0.998 
F7 0.997 0.977 0.998 
 
Evaluation of the selected formula of clopidogrel proniosomes 
Micromeritic properties 
Good flowability of powders is an important character in solid dosage 
forms to achieve better handling and processing. Results of micromeritic 
properties of maltodextrin and the selected proniosomal formulation 
were listed in table 8. It was observed that the angle of repose of 
clopidogrel proniosomal powder (31.67 °±0.49 °) was lower than that of 
maltodextrin (46.12 °±0.53 °). Flowability is represented by the angle of 
repose (θ). A value of θ between 25-30 ° indicates excellent flow, a value 
of θ between 31–35 ° indicates good flow, a value of θ between 36–40 ° 
indicates fair flow, a value of θ between 41–45 ° indicates passable flow, 
a value of θ between 46–55 ° indicates ‘poor’ flow and a value of θ higher 
than 56 ° indicates ‘very poor’ flow [42]. Based on this, the flow of 
clopidogrel proniosomes was rated as good flow, whereas the flow of 
maltodextrin was rated as poor flow. These results showed that 
proniosomal formula is of good flowability that is higher than that of 
maltodextrin powder. 
 
Table 8: Micromeritic properties of maltodextrin and selected proniosomal formula (F1) 
Formulation Angle of repose 
Maltodextrin 46.12 °±0.53 ° 
Proniosomal formula (F1) 31.67 °±0.49 ° 
P
*
PData are expressed as mean±SD, n=3 
 
Photomicroscopic examination 
Examination of the chosen proniosomal formula under an optical 
microscope, fig. 2 showed that the surface of clopidogrel 
proniosomes was irregular due to a coating of the molecules of Span 
60 and cholesterol over the surface of maltodextrin [15]. Moreover, 
proniosomes were progressively and rapidly converted to niosomes 
upon addition of the aqueous phase due to swelling of the bilayers 
and vesicles by an interaction of water with the hydrophilic groups 
of surfactant. The swelled bilayers tend to form spherical structures 
giving rise to multi-lamellar and multi-vesicular structures that are 
converted to unilamellar niosomal vesicles upon sonication.  
Our results agree with those reported by Singh et al. (2012) [43]. 
  
 
Fig. 2: Optical photomicrograph of (a) proniosomal clopidogrel powder (10×) (b) proniosomal clopidogrel moist powder before 
sonication (40×), and (c) clopidogrel niosomes after sonication (40×) 
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Scanning electron microscopy (SEM)  
The SEM micrograph of the chosen proniosomal formula is illustrated 
in fig. 3. It was observed that the niosomal vesicles formed by 
hydration of proniosomes were discrete and spherical in shape with 
sharp boundaries. This may be attributed to the fact that the non-ionic 
surfactants form a closed bilayer vesicle in water based on its 
amphoteric nature using some energy like physical agitation or heat 
[44]. Spherical shape of niosomes may be attributed to their tendency 
to minimize their surface free energy. That is in accordance with the 
results reported by Das and Palei (2011) [45]. 
 
 
Fig. 3: Scanning electron micrograph of hydrated proniosomes 
of clopidogrel (F1) 
 
Vesicle size and zeta potential determination 
The particle size distribution of the chosen proniosomal formula 
showed unimodal normal symmetrical frequency distribution 
patterns, fig. 4. The mean vesicle size of the hydrated clopidogrel 
proniosomes was 217.9 nm. The polydispersity index, PDI, is an 
important parameter that describes the vesicle size distribution and 
it varies from 0.0 to 1.0. As the PDI value is closer to zero, the more 
homogenous the vesicles size. PDI was 0.005 indicating a narrow 
and homogenous size distribution [46]. 
 
 
Fig. 4: Particle size distribution curve of clopidogrel 
proniosomal formula (F1) 
 
The stability of colloidal dispersion is described by zeta 
potential. The colloidal dispersion that has large positive or 
negative zeta potential is considered to be stable. The chosen 
clopidogrel proniosomal formula has a positive zeta potential 
value (+17.65 mv) indicating that the chosen proniosomal 
formula is stable, fig. 5. Zeta potential is a measure of the net 
charge of niosomes. This high charge on the vesicle surface 
produces repulsion between the vesicles that make them stable 
without agglomeration providing a uniformly distributed 
suspension [10]. The positive value of zeta potential could be 
attributed to the presence of the nitrogen atom in the structure 
of cationic clopidogrel bisulphate [47]. This positive charge 
dominates over cholesterol and the neutral charge of Span 60. 
Our results are in agreement with Sengodan et al. (2009)[13]. 
 
Fig. 5: Zeta potential distribution of clopidogrel proniosomal 
formula (F1) 
 
Fourier transform infrared spectroscopy (FTIR) 
The FTIR spectra of clopidogrel, Span 60, cholesterol, maltodextrin, 
drug-free proniosomes and the chosen clopidogrel proniosomal 
formula (F1) were illustrated in fig. 6. The FTIR spectrum of 
clopidogrel showed characteristic peaks of clopidogrel which were 
absorption band at 2544 cm–1 which is due to (N+-H), 1751 cm–1 
(C=O, stretching), 1190 cm–1(C-O, stretching), 1030 cm-1 (C-O) [48]. 
Span 60 exhibited characteristic peaks at 3410 which is due to 
aliphatic O–H stretch, 2936 cm-1 (C–H stretch) and 1745 cm-1 (C =O 
stretch of ester). The characteristic peaks of cholesterol appeared at 
3400 cm–1 (OH stretching) and the observed bands between 2800–
3000 cm−1 are due to asymmetric and symmetric stretching 
vibrations of CH2 and CH3 groups. [49]. FTIR spectrum of 
maltodextrin showed an absorption band at 3399 cm-1 for OH group, 
a strong broadband between 980 cm-1 and 1200 cm-1 which is the 
most characteristic band for polysaccharides. The peaks at 1152 cm–
1 and 1018 cm–1
 
Fig. 6: FTIR spectrum of clopidogrel (a), Span 60 (b), cholesterol 
(c), maltodextrin (d), plain proniosomes (e) and the chosen 
clopidogrel proniosomal formula (f) 
 
Differential thermal analysis (DTA) study  
 were attributed to C–O stretching [50]. IR spectrum 
of plain proniosomes exhibited the characteristic peaks of 
cholesterol, Span 60 and maltodextrin with the reduced intensity 
that may be due to the formation of the lipid bilayer. FTIR spectrum 
of the selected proniosomal formula exhibited the characteristics 
peaks of clopidogrel that confirmed the absence of any chemical 
interactions between clopidogrel and other excipients [12]. 
Reduced-intensity and minor shifting of the characteristic peaks of 
clopidogrel may be explained on the basis of formation of Van der 
Wall forces, hydrogen bonds or dipole-dipole interactions between 
clopidogrel and other proniosome contents leading to the formation 
of stable proniosomal vesicles with high entrapment efficiency of the 
drug [49].  
 
DTA could be used to detect the thermal behavior and physical state 
of drug. DTA thermograms of clopidogrel, Span 60, cholesterol, 
Mazyed et al. 
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maltodextrin, plain (drug-free) proniosomes and the chosen 
proniosomal formula are presented in fig. 7. The DTA thermogram of 
clopidogrel showed a sharp endothermic peak at 179 °C which is 
corresponding to its melting point and indicated the crystallinity of 
clopidogrel [2]. Span 60, cholesterol and maltodextrin showed 
endothermic peaks at 54.4 °C, 144.2 °C and 294.9 °C corresponding 
to their transition temperatures, respectively [51, 52]. The plain 
proniosomes exhibited an appearance of a new endothermic peak at 
191.1 °C. That may be explained on the basis of interaction of the 
proniosome components during the formation of the lipid bilayer 
[49]. The chosen proniosomal formula (F1) showed the shift of the 
endothermic peak of the lipid bilayer to 199 °C and disappearance of 
the endothermic peak of clopidogrel. These findings are in 
accordance with results reported by Patil (2015) [53]. These 
findings might suggest a change of clopidogrel structure from 
crystalline to amorphous state due to high entrapment efficiency of 
clopidogrel into proniosomes [54]. That may be the cause of the 
enhanced dissolution of clopidogrel from proniosomes because 
amorphous state contains no crystal lattice interactions or bonds 
that need to be broken [55].  
 
 
Fig. 7: DTA thermogram of clopidogrel (a), Span 60 (b), 
cholesterol (c), maltodextrin (d), plain proniosomes (e) and the 
chosen clopidogrel proniosomal formula (f) 
 
In vivo study 
The In vivo behavior of the chosen proniosomal formulation (F1) 
was studied by measuring antiplatelet activity in adult male mice 
using platelet aggregation inhibition study and INR Measurement.  
Effect of clopidogrel proniosomal formula (F1) on platelet aggregation  
The effect of the chosen clopidogrel proniosomal formula (F1) on 
platelet aggregation was measured as bleeding time and bleeding 
volume. Our results showed that clopidogrel proniosomal formula (F1) 
significantly (p ≤ 0.001) increased the bleeding time (6.82±1.4) min 
compared to both control group (1.99±0.27) min as well as clopidogrel 
group (3.32±0.33) min after 1 h of treatment. The results obtained after 
3 h of treatment further confirmed the inhibitory effect of the 
proniosomal formula on platelet aggregation. The bleeding time in mice 
treated with F1 reached up to (9.860±1.710) min which was significantly 
(P<0.001) different from outcomes of control group (2.05±0.37) min and 
clopidogrel-treated group (5.11±0.54) min, (fig. 8A).  
Moreover, the bleeding volume 1 h after treatment with clopidogrel 
proniosomal formula (F1) (0.22±0.019) ml was significantly 
(P<0.001) greater than control group (0.11±0.01) ml and 
clopidogrel group (0.17±0.02) ml. Similarly, after 3 h of treatment, 
the bleeding volume of mice treated with F1 (0.31±0.04) ml was 
significantly (P<0.001) higher than control group (0.15±0.02) ml 
and clopidogrel group (0.21±0.04) ml (fig. 8 B). 
Effect of clopidogrel proniosomal formula (F1) on coagulation profile  
The effect of the chosen clopidogrel proniosomal formula (F1) on 
the coagulation profile was measured using coagulation markers 
such as prothrombin time and prothrombin activity as well as INR. 
The results of this study showed that clopidogrel as proniosomes 
was more potent compared to clopidogrel aqueous dispersion 
where 3 h post-treatment, clopidogrel proniosomal formula (F1) 
significantly (P<0.05) prolonged prothrombin time to (15.5±0.57) min 
and decreased prothrombin activity to (62.35%±5.28) and 
consequently increased the INR up to (1.52±0.12) compared to plain 
clopidogrel suspension that showed (14.17±0.36) min, (71.95%±1.76) 
and (1.33±0.05) for prothrombin time, prothrombin activity and INR 
respectively. The outcomes of the two groups were significantly 
(P<0.01) different from those obtained from a control group that 
showed prothrombin time, prothrombin activity and INR equal to 
(12.64±0.71 min, 82.64%±4.6, 1.15±0.07) respectively (fig. 9).  
The above data agree with results reported by Karabulut et 
al.(2004)[56]. Moreover, from the above results, it is clear that the 
formulation of clopidogrel as proniosomes improved the antiplatelet 
effect of clopidogrel. That may be attributed to the enhancement of 
solubility and bioavailability of clopidogrel following formulation as 
proniosomes. These results are in accordance with Wen et al. (2011) 
[57] and Sengodan et al.(2009)[13] who reported that the prepared 
proniosomal formulation showed higher pharmacological effect than the 
plain drug. In addition, Ali et al.(2015) observed that liposomes of 
clopidogrel were more effective in the inhibition of platelet aggregation 
than orally administered clopidogrel [30]. Therefore, Proniosomes are 
emerging strategy for more effective drug delivery [58]. 
 
 
Fig. 8: Effect of clopidogrel proniosomal formula (F1) on platelet aggregation, P*Pvalues of test group are compared with control group: a (p 
≤ 0.05), aa (p ≤0.01), aaa (p ≤ 0.001) and compared with Clopidogrel group: b (p ≤ 0.05), bb (p ≤0.01), bbb (p ≤ 0.001), P*PData are expressed 
as mean±SD, n=5 
Mazyed et al. 




Fig. 9: Effect of clopidogrel proniosomal formula on coagulation profile, *values of test group are compared with control group a (p ≤ 
0.05), aa (p ≤0.01), aaa (p ≤ 0.001) and compared with Clopidogrel group b (p ≤ 0.05), bb (p ≤0.01), bbb (p ≤ 0.001), *
 
Data are expressed 
as mean±SD, n=5 
CONCLUSION 
The present study deals with developing clopidogrel proniosomes. 
Clopidogrel-based proniosomes were successfully prepared as free-
flowing powders with high entrapment efficiency in the range of 
83.04±1.99 to 90.14±0.30. The proniosomal formulations showed higher 
dissolution profile than the plain drug. F1 (clopidogrel proniosomes 
prepared with cholesterol and Span 60 in 40: 210 molar ratio) showed 
the highest in vitro release over other proniosomal formulations. F1 was 
found to be free-flowing powder of good flowability that is higher than 
that of maltodextrin powder. The niosomal vesicles formed by hydration 
of F1 proniosomes were spherical in shape with mean vesicle size of 
217.9 nm with zeta potential value (+17.65 mv). FTIR study con firmed 
the absence of any chemical interactions between clopidogrel and other 
excipients. DTA study showed a change of clopidogrel structure from 
crystalline to an amorphous state. In vivo test showed that clopidogrel 
proniosomal formula enhanced the antiplatelet activity of clopidogrel. 
This approach could be promising in enhancing the dissolution, 
bioavailability, and efficacy of clopidogrel as well as to decrease its 
adverse effects. 
AUTHORS CONTRIBUTIONS 
All authors have contributed equally 
CONFLICT OF INTERESTS 
All authors have declared no conflict of interest 
REFERENCES 
1. Sanjaymitra PVSS, Ganesh GNK. Dissolution and solubility 
enhancement strategies: current and novel prospectives. J Crit 
Rev 2018;5:1-10. 
2. Jassim ZE, Hussein AA. Formulation and evaluation of 
clopidogrel tablet incorporating drug nanoparticles. Iran J 
Pharm Sci 2014;6:838–51. 
3. Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation 
and applications. Int J Pharm Stud Res 2012;3:14–20. 
4. Sharma Vijay K, Mishra DN, Sharma AK, Srivastava B. 
Liposomes: present prospective and future challenges. Int J 
Curr Pharm Rev Res 2010;1:6–16.  
5. Ulrich AS. Biophysical aspects of using liposomes as delivery 
vehicles. Biosci Rep 2002;22:129–50. 
6. Kumar D, Sharma D, Singh G, Singh M, Rathore MS. Lipoidal soft 
hybrid biocarriers of supramolecular construction for drug 
delivery. ISRN Pharm 2012. http://dx.doi.org/10.5402/ 
2012/474830. 
7. Yadav K, Yadav D, Saroha K, Nanda S, Mathur P, Syan N. 
Proniosomal gel: a provesicular approach for transdermal drug 
delivery. Der Pharm Lett 2010;2:189–98. 
8. Yasam VR, Jakki SL, Natarajan J, Kuppusamy G. A review on 
novel vesicular drug delivery: proniosomes. Drug Delivery 
2014;21:243–9. 
9. Solanki A, Parikh J, Parikh R. Preparation, characterization, 
optimization, and stability studies of aceclofenac proniosomes. 
Iran J Pharm Res 2008;7:237–46. 
10. Samy AM, Ramadan AA, Abu El-Enin ASM, Mortagi YIM. 
Formulation and optimization of itraconazole proniosomes 
using box behnken design. Int J Appl Pharm 2018;10:41-51. 
11. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based 
formulations: optimizing the oral delivery of lipophilic drugs. 
Nat Rev Drug Discovery 2007;6:231-48. 
12. Boddu M, Choppari V, Rapalli VK, Badam M. Formulation and 
evaluation of proniosomes of felodipine. Drug Des 2017;6:154. 
13. Sengodan T, Sunil B, Vaishali R, Chandra RJ, Nagar S, Nagar O. 
Formulation and evaluation of maltodextrin based proniosomes 
loaded with indomethacin. Int J PharmTech Res 2009;1:517–23. 
14. Marwa HA, Omaima AS, Hanaa AE, Hanan ME. Optimizing 
proniosomes for controlled release of ketoprofen using a box-
behnken experimental design. Int J Pharm Sci Res 2011;2:2195. 
15. Chauhan MK, Sahoo PK, Rawat AS, Duggal D, Kandwal M, 
Sandal N. Formulation, characterization and in vitro evaluation 
of tactically engineered proniosomes for successful oral 
delivery of ramipril. Der Pharm Lett 2015;7:93–7. 
16. El Maghraby GM, Ahmed AA, Osman MA. Penetration 
enhancers in proniosomes as a new strategy for enhanced 
transdermal drug delivery. Saudi Pharm J 2015;23:67–74. 
17. Moore JW, Flanner HH. Mathematical comparison of curves 
with an emphasis on in vitro dissolution profile. Pharm Technol 
1996;20:64-74. 
18. Samy AM, Ghorab MM, Shadeed SG, Mazyed EA. Formulation 
and evaluation of different transdermal drug delivery systems 
of ketoprfen. Int J Pharm Pharm Sci 2013;5 Suppl 2:600-7. 
19. Nyol S, Gupta MM. Immediate drug release dosage form: a 
review. J Drug Delivery Ther 2013;3:155-61. 
20. AhmedIbrahiem MM. Proniosomal oral tablets for controlled 
delivery and enhanced pharmacokinetic properties of 
Acemetacin. AAPS 2014;16:375-83. 
21. Sivannarayana P, Rani AP, Saikishore V, Venu Babu C, Sri Rekha 
V. Transfersomes: ultra deformable vesicular carrier systems in 
transdermal drug delivery system. Res J Pharm Dos Forms 
Technol 2012;4:243-5. 
22. Das B, Sen SO, Maji R, Nayak AK, Sen KK. Transferosomal gel for 
transdermal delivery of risperidone: formulation optimization and 
ex vivo permeation. J Drug Delivery Sci Technol 2017;38:59–71. 
23. Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. 
Design and development of a proniosomal transdermal 
drug delivery system for captopril. Trop J Pharm Res 
2007;6:687–93. 
Mazyed et al. 
Int J App Pharm, Vol 11, Issue 2, 2019, 77-85 
 
85 
24. Maheswari U, Mullaicharam AR. Development and in vitro 
evaluation of nanosuspension formulation containing acyclovir 
for the treatment of ocular infections. Res J Pharm Biol Chem 
Sci 2013;4:463–80. 
25. Trivedi MK, Branton A, Trivedi D, Nayak G, Mishra R, Jana S. 
Characterization of physical, thermal and spectral properties of 
biofield treated 2-aminopyridine. Sci J Anal Chem 2015;3:127–34. 
26. Eid RK, Essa EA, El Maghraby GM. Essential oils in niosomes for 
enhanced transdermal delivery of felodipine. Pharm Dev 
Technol 2018;23:1–9. 
27. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. 
Improving bioscience research reporting: the ARRIVE 
guidelines for reporting animal research. PLoS Biol 
2010;8:e1000412. 
28. 2010/63/EU EU directive. Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 
on the protection of animals used for scientific purposes. Off J 
Eur Union L 2010;276:33–79. 
29. de Vries JW, Schnichels S, Hurst J. DNA nanoparticles for 
ophthalmic drug delivery. Biomaterials 2018;157:98–106. 
30. Ali SM, Sheikh S, Ahmad A, Moghis U. Pre-clinical and phase i 
clinical study of clopidogrel lipid suspension: intravenously 
injected formulation results in the faster onset of action and 
dose-dependent inhibition of platelet aggregation. J Pharmacol 
Clin Toxicol 2015;3:1–8. 
31. Murad JP, Espinosa EVP, Ting HJ, Khasawneh FT. 
Characterization of the in vivo antiplatelet activity of the 
antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 
2012;17:308–14. 
32. Foerch C, Arai K, Jin G. Experimental model of warfarin-
associated intracerebral hemorrhage. Stroke 2008;39:3397–
404. 
33. Lemini C, Jaimez R, Franco Y. Gender and inter-species 
influence on coagulation tests of rats and mice. Thromb Res 
2007;120:415–9. 
34. Gurrapu A, Jukanti R, Bobbala SR, Kanuganti S, Jeevana JB. 
Improved oral delivery of valsartan from maltodextrin based 
proniosome powders. Adv Powder Technol 2012;23:583–90. 
35. Nii T, Ishii F. Encapsulation efficiency of water-soluble and 
insoluble drugs in liposomes prepared by the 
microencapsulation vesicle method. Int J Pharm 
2005;298:198–205. 
36. Singh CH. Formulation, characterization, stability and in vitro 
evaluation of nimesulide niosomes. Pharmacophore 
2011;2:131–48. 
37. Sankar V, Ruckmani K, Durga S, Jailani S. Proniosomes as drug 
carriers. Pak J Pharm Sci 2010;23:103–7. 
38. Ibrahim MM, Tawfique SAH, Mahdy MM. Liposomal diltiazem 
HCl as ocular drug delivery system for glaucoma. Drug Dev Ind 
Pharm 2014;40:765–73. 
39. Mokhtar ASZ and M. Multivariate optimization of formulation 
variables influencing flurbiprofen proniosomes characteristics. 
J Pharm Sci 2011;100:2212–21. 
40. Asthana GS, Sharma PK, Asthana A. In vitro and in vivo 
evaluation of niosomal formulation for controlled delivery of 
clarithromycin. Scientifica (Cairo) 2016. Doi: 10.1155/ 
2016/6492953. 
41. Mokale VJ, Patil HI, Patil AP, Shirude PR, Naik JB. Formulation 
and optimisation of famotidine proniosomes: an in vitro and ex 
vivo study. J Exp Nanosci 2016;11:97–110. 
42. USP30-NF25, U. P., US Pharmacopoeial Convention, Inc, Rock. 
USA; 2007. 
43. Singh S, Trivedi S, Jain S. Design and development of 
proniosome based transdermal delivery of ondansetron 
hydrochloride. Int J Pharm Biol Res 2012;3:191–201. 
44. Kazi KM, Mandal AS, Biswas N. Niosome: a future of targeted 
drug delivery systems. J Adv Pharm Technol Res 2010;1:374–
80. 
45. Das MK, Palei NN. Sorbitan ester niosomes for topical delivery 
of rofecoxib. Indian J Exp Biol 2011;49:438-45. 
46. Keservani RK, Sharma AK, Jain S. Effect of different process 
variables on the preparation of baclofen niosomes. Int J Univ 
Pharm Life Sci 2011;1:301–10. 
47. Balasubramaniam J, Bindu K, Rao VU, Ray D, Haldar R, 
Brzeczko AW. Effect of superdisintegrants on a dissolution of 
cationic drugs. Dissolution Technol 2008;15:18-25. 
48. Patel P. Design and development of self microemulsifying drug 
delivery system of clopidogrel bisulphate. Int J Pharmamedix 
India 2013;1:539–53. 
49. El-Sayed MM, Hussein AK, Sarhan HA, Mansour HF. 
Flurbiprofen-loaded niosomes-in-gel system improves the 
ocular bioavailability of flurbiprofen in the aqueous humor. 
Drug Dev Ind Pharm 2017;43:902–10. 
50. Sun P, Yang HJ, Wang YQ, Liu KZ, Xu YW. Lipase-catalyzed 
synthesis and characterization of stearic acid dextrin ester. Res 
Heal Nutr 2013;1:7–11. 
51. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, 
Ramly AEl. Formulation of tretinoin-loaded topical 
proniosomes for treatment of acne: in vitro characterization, 
skin irritation test and comparative clinical study. Drug 
Delivery 2015;22:731–9. 
52. Das S. Study of decomposition behaviour of binders and the 
effect of binder type on strength and density of alumina 
samples, BTech Thesis, Department of Ceramic Engineering, 
National Institute of Technology Rourkela; 2011. 
53. Patil BA. Formulation and development of industry feasible 
proniosomal transdermal drug delivery system of granisetron 
hydrochloride. Asian J Pharm 2015;9:113–9. 
54. Patil HN, Hardikar SR, Bhosale AV. Formulation, development 
and evaluation of proniosomal gel of carvedilol. Int J Pharm 
Pharm Sci 2012;4:191–7. 
55. Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Development 
and in vitro/in vivo evaluation of controlled release provesicles 
of a nateglinide–maltodextrin complex. Acta Pharm Sin B 
2014;4:408–16. 
56. Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, 
Alhan C. Clopidogrel does not increase bleeding and allogenic 
blood transfusion in coronary artery surgery. Eur J Cardio-
Thoracic Surg 2004;25:419–23. 
57. Wen MM, Farid RM, Kassem AA. Nano-proniosomes enhancing 
the transdermal delivery of mefenamic acid. J Liposome Res 
2014;24:280–9. 
58. Vasistha P, Ram A. Non-ionic provesicular drug carrier: an 
overview. Asian J Pharm Clin Res 2013;6 Suppl 1:38-42. 
 
